Skip to main content

Pediatrics

Many activities conducted within FDA’s Sentinel System are aimed at gaining a better understanding of the pediatric patient population. These include studies that estimate rates of specific health outcomes, as well as studies that examine prevalent and incident use of medical products, among pediatric patients in the Sentinel System. Descriptions of efforts led by the Center for Drug Evaluation and Research are shown below. Please visit the links to learn more about each area of activity. 

Title Date
Beta-Blocker-Associated Hypoglycemia in Pediatric Patients: Findings from the FDA Adverse Event Reporting System, National Poison Data System, Medical Literature, and Sentinel Distributed Database
Pediatric Utilization of New Molecular Entities (NMEs): A Summary of Early Post-Marketing Uptake in the Sentinel Distributed Database
Utilization of Beta-blockers Among the Pediatric Population in the United States: A Study in the FDA’s Sentinel System from 2008 to 2022
Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis
Treatment and Care Received by Children Hospitalized with COVID-19 in a Large Hospital Network in the United States, February 2020 to September 2021
Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations
Valganciclovir Use in Children with Congenital Cytomegalovirus Infection: Chart Review
Characterizing Pediatric Members in the Sentinel Distributed Database
Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis
Pilot Test of Vital Signs and Laboratory Results Table Descriptive Modules in the Sentinel Distributed Database
Hypertension in Pediatric Patients: A Descriptive Analysis
Use of Typical and Atypical Antipsychotics Among Infants
Respiratory Syncytial Virus in a Pediatric Population
Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) in a Pediatric Population
Pulmonary Arterial Hypertension and Interstitial Lung Disease Events Among Interleukin Inhibitor Users